At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Apr 30, 2026 at 20:00 ET
Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades represent only ~0.05% of market cap and are likely routine portfolio management, not a bearish signal. Q1 revenue grew 4.9% YoY to $164.9M, but the company reported a net loss of $31.8M vs net income of $20.5M in the prior year, driven by increased spending on the Lifyorli launch.
- CEO Belanoff sold 40,000 shares at ~$50.10 for $2.00M on May 1, 2026.
- CDO Guyer sold 20,000 shares at ~$51.83 for $1.04M on May 5, 2026 (also exercised options with no cash impact).
- Total insider sales of $3.04M represent ~0.054% of $5.6B market cap.
- Q1 2026 revenue rose 4.9% YoY to $164.9M; net loss of $31.8M vs net income of $20.5M in Q1 2025.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access